Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

in 40 preclinical abstracts presented at scientific congresses, and 15 original peer-reviewed scientific manuscripts in leading scientific journals, plus 17 review articles and commentaries in the literature. Most recently 8 presentations were made at the American Association for Cancer Research in April, where ibrutinib was evaluated preclinically in various disease settings.

Today over 1300 patients have been dosed with ibrutinib in company sponsored trials. Together with our collaboration partner Janssen, Pharmacyclics has engaged upwards of approximately 250 clinical sites, using ibrutinib in CLL, and additionally over 100 clinical sites engaged for the use of ibrutinib in MCL. These numbers are continuously growing as new studies are being initiated within the overall clinical development program. As of today there are over 28 studies registered with the U.S. National Institutes of Health. Five of these studies are Phase III trials, which each enrolling approximately 300-600 patients. Several of the trials in our clinical program are sponsored by the National Cancer Institute or other medical centers. To date ibrutinib is being clinically advanced in over 25 countries, which include the major population regions: U.S., Europe, Asia Pacific and Latin America.

Phase II / III / IV Clinical Trials Initiated with Ibrutinib Over the Last 12 Months

  • A multicenter, open label Expanded Access Program for ibrutinib in R/R MCL patients (MCL4001) is being initiated in the US by Janssen. In the time before a potential U.S. marketing approval, Pharmacyclics and Janssen will strive to provide early access to ibrutinib under an Expanded Access Program (EAP). EAPs are clinical studies allowed under certain circumstances by the FDA. They are designed to provide a mechanism for access to an investigational drug to treat patients with a serious or immediately life-threatening diseases or conditions until the time of an anticipated U.S. marketing approval. Fur
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
    (Date:12/24/2014)... Pa. , Dec. 24, 2014  Commonwealth Cornerstone Group ... Markets Tax Credits transaction on Tuesday to help fund the ... Network (PHN) in Sharon . ... in Pennsylvania . It is the largest ... with more than 150 people on staff. Currently, ...
    (Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
    Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
    ... announces that a new market research report is ... Cardiac Defibrillators Industry http://www.reportlinker.com/p098394/Global-Cardiac-Defibrillators-Industry.html ... markets for Cardiac Defibrillators in Units and US$ ... analyzed by the following segments - Implantable/Internal Cardiac ...
    ... 24, 2011 Reportlinker.com announces that a new ... Global ECG Telemetry Devices Industry ... This report analyzes the worldwide markets for ... following Product Segments: Patient Digital Transmitters, Electrical Leads, ...
    Cached Medicine Technology:Reportlinker Adds Global Cardiac Defibrillators Industry 2Reportlinker Adds Global ECG Telemetry Devices Industry 2
    (Date:12/26/2014)... December 26, 2014 The Biofeedback Federation ... March 24-28, 2015 in Rome, Italy and is hosted ... workshops on a wide variety of topics ... as peak performance training in athletes. The scientific program ... world. , Biofeedback monitoring allows clients to see what ...
    (Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
    (Date:12/25/2014)... TX (PRWEB) December 26, 2014 This ... state of the global Sterilizers industry with a focus ... on the market status of the Sterilizers manufacturers and ... companies and individuals interested in the industry. This report ... definition, applications and manufacturing technology. In this part, the ...
    (Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
    (Date:12/25/2014)... The short film “Color of Honor” by young director/producer ... true 9/11 hero, Welles Remy Crowther. It has been chosen ... of Nuremberg International Short Film Festival and the 8th International ... and director Luciana Lagana plays the mother of the ... Gregory Graham - Graham plays a heroic policeman ...
    Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
    ... Social Media Guru Mashable.com Cites Organizations Using Social Media for ... July 1 The Oral Cancer Foundation was recently praised ... discussing non-profit organizations that are effectively using Internet-based social media ... focused exclusively on Web 2.0 and social media such as ...
    ... Zufall Health Center, a federally qualified health center operating ... eco-friendly mobile medical unit. , , The Highlands ... to low-income, mostly uninsured residents of Hunterdon, Warren and ... at a ribbon cutting ceremony in Flemington. , ...
    ... transplantation offers a good chance for survival for patients ... factors are associated with worse outcomes. Patients who are ... children whose liver failure was caused by antiepileptic drugs ... are in the July issue of Liver Transplantation ...
    ... TeamHealth Demonstrates Ongoing Commitment to Patient Care through Patient ... 1 TeamHealth announced today that it has been ... On July 1, its patient safety organization -- the ... the Agency for Healthcare Research and Quality (AHRQ), the ...
    ... ... vivid personal stories about Internet dating and end-of-life dilemmas. Some stories will be used for ... Kenner. , ... 1, 2009 -- Kayce Freed Jennings, the wife of late ABC newsman Peter Jennings, and Marc ...
    ... what remains unclear , WEDNESDAY, July 1 (HealthDay News) -- ... more common in recent years, a new Mayo Clinic study ... issue of Gastroenterology , the disease is four times ... 1950s. In addition, the researchers found that the death rate ...
    Cached Medicine News:Health News:Oral Cancer Foundation Praised for Its Social Media Efforts 2Health News:Nation's First Eco-Friendly Mobile Health Van Launched by New Jersey Non-Profit Health Center 2Health News:Nation's First Eco-Friendly Mobile Health Van Launched by New Jersey Non-Profit Health Center 3Health News:Study examines liver transplantation after drug induced acute liver failure 2Health News:Study examines liver transplantation after drug induced acute liver failure 3Health News:TeamHealth Recognized by National Quality Agency 2Health News:TeamHealth Recognized by National Quality Agency 3Health News:First-Person Stories Gathered on Web Shape New Nonfiction TV Series from Veteran Producers 2Health News:First-Person Stories Gathered on Web Shape New Nonfiction TV Series from Veteran Producers 3Health News:First-Person Stories Gathered on Web Shape New Nonfiction TV Series from Veteran Producers 4Health News:Celiac Disease Making Inroads in U.S. 2
    Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
    For the quantitative in vitro determination of Ammonia in plasma...
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    Medicine Products: